Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Search
HBA Rising Star & Luminary Awards | Boehringer Ingelheim US
Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.
Driving Innovation through Diversity & Inclusion
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Partnering for Innovation in Animal Health
Video with Erik Haaksma and Megan Grether describing how partnering is an essential component of innovation at Boehringer Ingelheim Animal Health.
Boehringer Ingelheim Fremont, Inc.
Fremont, California, is the home of Boehringer Ingelheim’s rapidly growing US Biopharmaceuticals Business Unit
Celebrating Innovation | Partnering
BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.
Boehringer Ingelheim Innovation Prize Video 2023
Video providing an overview of the Innovation Prize initiative and the benefits of participating and receiving the award.
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Welcome to Innovation @ Boehringer Ingelheim
Welcome to Innovation @ Boehringer Ingelheim
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
Focus on Alliance Management
Focus on Alliance Management
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Exploring T-cells in cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop
Our Partnering Approach in Animal Health
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund